::: Svein Lien appointed new CEO of Biotec Pharmacon ASA
Svein Lien, new CEO of Biotec Pharmacon ASA, Chairman of the Board Svein Mathisen, CEO Lars Viksmoen, Biotec Pharmacon ASA, Biotec Marine Biochemicals, development phase, pharmaceutical development program, experienced CEO, pharmaceutical opportunities

::: Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
TECNIS Multifocal 1-Piece lens, TECNIS Multifocal optic lens, begun shipping TECNIS Multifocal 1-Piece IOLs, Multifocal 1-Piece intraocular lens, TECNIS lens, TECNIS multifocal IOLs, New Cataract Multifocal Intraocular Lens, TECNIS Multifocal 3-Piece IOL, removal of the natural lens, Medicare cataract patients

::: New capital for the navigated tumor surgery: FVW and Clusterfonds Innovation invest in SurgicEye
SurgicEye system, tumor surgery of the SurgicEye GmbH, SurgicEye solution outperforms, team of SurgicEye, Chairman of SurgicEye, past 12 months SurgicEye, CEO of the SurgicEye GmbH, explains Dr, states Dr, breast cancer surgery

::: Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis
Orphan Drug Designation, orphan drug status, ALS patients, novel drug candidate, promising drug candidate, lead drug candidate, Drug Administration, clinical development, Evidence of Effect clinical trial

::: Cempra Announces the Completion of Phase 1 Studies for CEM-101, a Next-Generation Macrolide
intravenous formulation of CEM-101, severe community-acquired bacterial pneumonia, advancing CEM-101, initiate Phase 2 studies, Completion of Phase 1 Studies, successful completion of Phase 1 clinical trials, oral formulation of CEM-101, intravenous formulation available, Cempra Pharmaceuticals, Phase 1 IND